Advertisement

Chemotherapy for Temporal Bone Cancer

  • Renata Ferrarotto
  • Merrill S. Kies
Chapter

Abstract

Temporal bone cancer (TBC) is rare, accounting for less than 0.2% of malignancies arising in the head and neck. Surgery, whenever possible, is the main treatment modality for TBC. Patients with locally advanced or inoperable disease might be suitable for a curative intent multimodality approach including chemotherapy, surgery, radiotherapy or concurrent chemoradiation. Some TBC histological subtypes are sensitive to targeted therapy. Given its rarity and absence of prospective, randomized clinical trials, TBC are better managed by a multidisciplinary team in a tertiary referral center.

Keywords

Chemotherapy Targeted therapy Temporal bone cancer Squamous cell carcinoma Basal cell carcinoma 

References

  1. 1.
    Kuhel WI, Hume CR, Selesnick SH. Cancer of the external auditory canal and temporal bone. Otolaryngol Clin N Am. 1996;29(5):827–52.Google Scholar
  2. 2.
    Devaney KO, Boschman CR, Willard SC, Ferlito A, Rinaldo A. Tumours of the external ear and temporal bone. Lancet Oncol. 2005;6(6):411–20.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Pfreundner L, Schwager K, Willner J, Baier K, Bratengeier K, Brunner FX, et al. Carcinoma of the external auditory canal and middle ear. Int J Radiat Oncol Biol Phys. 1999;44(4):777–88.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Lobo D, Llorente JL, Suarez C. Squamous cell carcinoma of the external auditory canal. Skull Base. 2008;18(3):167–72.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Moody SA, Hirsch BE, Myers EN. Squamous cell carcinoma of the external auditory canal: an evaluation of a staging system. Am J Otol. 2000;21(4):582–8.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Takenaka Y, Cho H, Nakahara S, Yamamoto Y, Yasui T, Inohara H. Chemoradiation therapy for squamous cell carcinoma of the external auditory canal: a meta-analysis. Head Neck. 2015;37(7):1073–80.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Yin M, Ishikawa K, Honda K, Arakawa T, Harabuchi Y, Nagabashi T, et al. Analysis of 95 cases of squamous cell carcinoma of the external and middle ear. Auris Nasus Larynx. 2006;33(3):251–7.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Joshi A, Tandon N, Noronha V, Dhumal S, Patil V, Arya S, et al. Neoadjuvant chemotherapy in technically unresectable carcinoma of external auditory canal. Indian J Med Paediatr Oncol. 2015;36(3):172–5.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.PubMedCrossRefGoogle Scholar
  10. 10.
    Morita S, Homma A, Nakamaru Y, Sakashita T, Hatakeyama H, Kano S, et al. The outcomes of surgery and chemoradiotherapy for temporal bone cancer. Otol Neurotol. 2016;37(8):1174–82.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Ueda Y, Kurita T, Matsuda Y, Ito S, Nakashima T. Superselective, intra-arterial, rapid infusion chemotherapy for external auditory canal carcinoma. J Laryngol Otol Suppl. 2009;(31):75–80.CrossRefGoogle Scholar
  12. 12.
    Sugimoto H, Ito M, Yoshida S, Hatano M, Yoshizaki T. Concurrent superselective intra-arterial chemotherapy and radiotherapy for late-stage squamous cell carcinoma of the temporal bone. Ann Otol Rhinol Laryngol. 2011;120(6):372–6.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Rasch CR, Hauptmann M, Balm AJ. Intra-arterial chemotherapy for head and neck cancer: is there a verdict? Cancer. 2011;117(4):874. author reply; 874–5PubMedCrossRefGoogle Scholar
  14. 14.
    Lorch JH, Goloubeva O, Haddad RI, Cullen K, Sarlis N, Tishler R, et al. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol. 2011;12(2):153–9.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116–27.PubMedCrossRefGoogle Scholar
  16. 16.
    Ragi JM, Patel D, Masud A, Rao BK. Nonmelanoma skin cancer of the ear: frequency, patients’ knowledge, and photoprotection practices. Dermatol Surg. 2010;36(8):1232–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Xie J, Murone M, Luoh SM, Ryan A, Gu Q, Zhang C, et al. Activating smoothened mutations in sporadic basal-cell carcinoma. Nature. 1998;391(6662):90–2.PubMedCrossRefGoogle Scholar
  18. 18.
    Johnson RL, Rothman AL, Xie J, Goodrich LV, Bare JW, Bonifas JM, et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science. 1996;272(5268):1668–71.PubMedCrossRefGoogle Scholar
  19. 19.
    Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171–9.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Sekulic A, Migden MR, Lewis K, Hainsworth JD, Solomon JA, Yoo S, et al. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. J Am Acad Dermatol. 2015;72(6):1021–6.e8.PubMedCrossRefGoogle Scholar
  21. 21.
    Migden MR, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015;16(6):716–28.PubMedCrossRefGoogle Scholar
  22. 22.
    Cartei G, Cartei F, Interlandi G, Meneghini G, Jop A, Zingone G, et al. Oral 5-fluorouracil in squamous cell carcinoma of the skin in the aged. Am J Clin Oncol. 2000;23(2):181–4.PubMedCrossRefGoogle Scholar
  23. 23.
    Khansur T, Kennedy A. Cisplatin and 5-fluorouracil for advanced locoregional and metastatic squamous cell carcinoma of the skin. Cancer. 1991;67(8):2030–2.PubMedCrossRefGoogle Scholar
  24. 24.
    Reigneau M, Robert C, Routier E, Mamelle G, Moya-Plana A, Tomasic G, et al. Efficacy of neoadjuvant cetuximab alone or with platinum salt for the treatment of unresectable advanced nonmetastatic cutaneous squamous cell carcinomas. Br J Dermatol. 2015;173(2):527–34.PubMedCrossRefGoogle Scholar
  25. 25.
    Maubec E, Petrow P, Scheer-Senyarich I, Duvillard P, Lacroix L, Gelly J, et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol. 2011;29(25):3419–26.PubMedCrossRefGoogle Scholar
  26. 26.
    Foote MC, McGrath M, Guminski A, Hughes BG, Meakin J, Thomson D, et al. Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma. Ann Oncol. 2014;25(10):2047–52.PubMedCrossRefGoogle Scholar
  27. 27.
    Lewis CM, Glisson BS, Feng L, Wan F, Tang X, Wistuba II, et al. A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res. 2012;18(5):1435–46.PubMedCrossRefGoogle Scholar
  28. 28.
    Ferrarotto R, Heymach JV, Glisson BS. MYB-fusions and other potential actionable targets in adenoid cystic carcinoma. Curr Opin Oncol. 2016;28(3):195–200.PubMedCrossRefGoogle Scholar
  29. 29.
    Airoldi M, Pedani F, Succo G, Gabriele AM, Ragona R, Marchionatti S, et al. Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies. Cancer. 2001;91(3):541–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Licitra L, Cavina R, Grandi C, Palma SD, Guzzo M, Demicheli R, et al. Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients. Ann Oncol. 1996;7(6):640–2.PubMedCrossRefGoogle Scholar
  31. 31.
    Ferrarotto R, Mitani Y, Diao L, Guijarro I, Wang J, Zweidler-McKay P, et al. Activating NOTCH1 mutations define a distinct subgroup of patients with adenoid cystic carcinoma who have poor prognosis, propensity to bone and liver metastasis, and potential responsiveness to Notch1 inhibitors. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35(3):352–60.CrossRefGoogle Scholar
  32. 32.
    Grotz TE, Tarantola TI, Otley CC, Weaver AL, McGree ME, Jakub JW. Natural history of merkel cell carcinoma following locoregional recurrence. Ann Surg Oncol. 2012;19(8):2556–62.PubMedCrossRefGoogle Scholar
  33. 33.
    Ouaz K, Robier A, Lescanne E, Bobillier C, Moriniere S, Bakhos D. Cancer of the external auditory canal. Eur Ann Otorhinolaryngol Head Neck Dis. 2013;130(4):175–82.CrossRefGoogle Scholar
  34. 34.
    Mauzo SH, Ferrarotto R, Bell D, Torres-Cabala CA, Tetzlaff MT, Prieto VG, et al. Molecular characteristics and potential therapeutic targets in Merkel cell carcinoma. J Clin Pathol. 2016;69(5):382–90.PubMedCrossRefGoogle Scholar
  35. 35.
    Tai PT, Yu E, Winquist E, Hammond A, Stitt L, Tonita J, et al. Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: case series and review of 204 cases. J Clin Oncol Off J Am Soc Clin Oncol. 2000;18(12):2493–9.CrossRefGoogle Scholar
  36. 36.
    Devaney KO, Ferlito A, Rinaldo A. Endolymphatic sac tumor (low-grade papillary adenocarcinoma) of the temporal bone. Acta Otolaryngol. 2003;123(9):1022–6.PubMedCrossRefGoogle Scholar
  37. 37.
    Kawabata S, Hollander MC, Munasinghe JP, Brinster LR, Mercado-Matos JR, Li J, et al. Epidermal growth factor receptor as a novel molecular target for aggressive papillary tumors in the middle ear and temporal bone. Oncotarget. 2015;6(13):11357–68.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Sbeity S, Abella A, Arcand P, Quintal MC, Saliba I. Temporal bone rhabdomyosarcoma in children. Int J Pediatr Otorhinolaryngol. 2007;71(5):807–14.CrossRefGoogle Scholar
  39. 39.
    Raney RB, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM, et al. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. J Clin Oncol. 2011;29(10):1312–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Walterhouse DO, Pappo AS, Meza JL, Breneman JC, Hayes-Jordan AA, Parham DM, et al. Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(31):3547–52.CrossRefGoogle Scholar
  41. 41.
    Malempati S, Hawkins DS. Rhabdomyosarcoma: review of the Children’s Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies. Pediatr Blood Cancer. 2012;59(1):5–10.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Cascinelli N. Margin of resection in the management of primary melanoma. Semin Surg Oncol. 1998;14(4):272–5.PubMedCrossRefGoogle Scholar
  43. 43.
    Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2010;102(7):493–501.PubMedCrossRefGoogle Scholar
  44. 44.
    Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16(5):522–30.PubMedCrossRefGoogle Scholar
  45. 45.
    Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Cureoglu S, Tulunay O, Ferlito A, Schachern PA, Paparella MM, Rinaldo A. Otologic manifestations of metastatic tumors to the temporal bone. Acta Otolaryngol. 2004;124(10):1117–23.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(17):1974–82.CrossRefGoogle Scholar
  48. 48.
    Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856–67.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Chow LQ, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, et al. Antitumor activity of Pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol. 2016;34(32):3838–45.PubMedCrossRefGoogle Scholar
  50. 50.
    Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D’Angelo SP, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17(10):1374–85.PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, et al. PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med. 2016;374(26):2542–52.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Thoracic-Head and Neck Medical OncologyHoustonUSA

Personalised recommendations